throbber
UNITED STATES PATENT AND TRADEMARK OFFICE
` BEFORE THE PATENT TRIAL AND APPEAL BOARD
`
`- - - - - - - - - - - - - - - +
` |
`MYLAN PHARMACEUTICALS, INC., |
` |
` Petitioner, |
` |
` |
` vs. |
` |
`YEDA RESEARCH AND DEVLOPMENT |
`CO., LTD., |
` Patent Owner. |
` |
`- - - - - - - - - - - - - - - +
`
` Case IPR2015-00643 (8,232,250)
` Case IPR2015-00644 (8,399,413)
` Case IPR2015-00830 (8,969,302)
`
` Deposition of STEPHEN J. PEROUTKA, M.D.,
`Ph.D., taken on behalf of the Patent Owner Yeda, at
`901 New York Avenue, Washington, D.C., beginning at
`9:30 a.m. on October 29, 2015, before Michele E.
`Eddy, RPR, CRR, CLR, and Notary Public for the
`District of Columbia.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 1
`
`

`
`2
`
` A P P E A R A N C E S
`
`ON BEHALF OF THE PATENT OWNER YEDA:
` WILLIAM G. JAMES, ESQUIRE
` DANIEL P. MARGOLIS, Ph.D., ESQUIRE
` ELIZABETH J. HOLLAND, ESQUIRE
` Goodwin Procter LLP
` The New York Times Building
` 620 Eighth Avenue
` New York, New York 10018
` (212) 813-8800
` wjames@goodwinprocter.com
` dmargolis@goodwinprocter.com
` eholland@goodwinprocter.com
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 2
`
`

`
`3
`
`ATTENDANCE, Continued
`
`ON BEHALF OF MYLAN AND THE WITNESS:
` DAVID L. ANSTAETT, ESQUIRE
` SHANNON M. BLOODWORTH, ESQUIRE
` EMILY J. GREB, ESQUIRE
` Perkins Coie
` 700 13th Street, Northwest
` Suite 600
` Washington, D.C. 20005
` (202) 654-6200
` danstaett@perkinscoie.com
` sbloodworth@perkinscoie.com
` egreb@perkinscoie.com
`
`ON BEHALF OF MYLAN:
` MATTHEW J. BRESNAHAN, ESQUIRE
` Wilson Sonsini Goodrich & Rosati
` 12235 El Camino Real, Suite 200
` San Diego, California 92130
` (858) 350-2226
` mbresnahan@wsgr.com
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 3
`
`

`
`4
`
`ATTENDANCE, Continued
`
`ON BEHALF OF AMNEAL PHARMACEUTICALS:
` VINCENT L. CAPUANO, Ph.D., ESQUIRE
` Duane Morris, LLP
` 100 High Street, Suite 2400
` Boston, Massachusetts 02110
` (857) 488-4250
` vcapuano@duanemorris.com
`
`ALSO PRESENT:
` Lori Wolfe, Teva Pharmaceuticals
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 4
`
`

`
`5
`
` EXAMINATION INDEX
` PAGE
`EXAMINATION BY MR. JAMES 8
`EXAMINATION BY MR. ANSTAETT 218
`FURTHER EXAMINATION BY MR. JAMES 226
`
` E X H I B I T S
` (Attached to the Transcript)
`DEPOSITION EXHIBIT PAGE
`Exhibit 1 Declaration in the '250 IPR 9
`Exhibit 2 Declaration in the '413 IPR 9
`Exhibit 3 Declaration in the '302 IPR 9
`Exhibit 4 Document titled 32
` "Multiple Sclerosis" from
` PRA website
`Exhibit 5 U.S. Patent 8,232,250 38
`Exhibit 6 Decision by United States 45
` District Judge in case titled
` Endo versus Mylan
`Exhibit 7 Some or all of the prescribing 52
` information for Copaxone from
` 2009; Mylan Exhibit number 1052
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`2
`3
`4
`5
`
`6 7 8 9
`
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 5
`
`

`
` EXHIBIT INDEX CONTINUED
`
`6
`
`DEPOSITION EXHIBIT PAGE
`Exhibit 8 Summary Basis of Approval 60
` Document; '250 IPR Mylan Exhibit
` 1007; cover sheet: affidavit
` from Marlene S. Bobka
`Exhibit 9 Article entitled "A Single 122
` Amino Acid Difference Confers
` Major Pharmacological Variation
` Between Human and Rodent
` 5-HT1B receptors"
`Exhibit 10 Document entitled "Randomized 158
` Double-blind Dose Comparison
` Study of Glatiramer Acetate in
` Relapsing Remitting MS"
`Exhibit 11 Forte Press Release 164
`Exhibit 12 Abstract 650 entitled 175
` "Copolymer-1 - Copaxone
` Induces a Non-immunologic
` Activation of Connective Tissue
` Type Mass Cells"
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 6
`
`

`
` EXHIBIT INDEX CONTINUED
`
`7
`
`DEPOSITION EXHIBIT PAGE
`Exhibit 13 Document entitled "Copolymer-1 184
` Glatiramer Acetate in Relapsing
` Forms of Multiple Sclerosis,
` Open Multicenter Study of
` Alternate Day Administration"
`Exhibit 14 Paper entitled "Copolymer-1 in 207
` Relapsing Remitting Multiple
` Sclerosis, a Multicenter Trial";
` Mylan Exhibit 1009
`Exhibit 15 Judge's ruling 219
`Exhibit 16 Patent Application 209
` WO 2007/081975; Inventor Irit
` Pinchasi
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`1
`
`2 3
`
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 7
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`8
`
` P R O C E E D I N G S
` October 29, 2015
` Washington, D.C.
` - - -
` STEPHEN J. PEROUTKA, M.D., Ph.D.,
`having been duly sworn, testified as follows:
` EXAMINATION BY COUNSEL FOR THE PATENT OWNER
`BY MR. JAMES:
` Q Good morning, Dr. Peroutka.
` A Good morning.
` Q I haven't had a chance to introduce myself
`on the record. My name is Bill James. I work at
`Goodwin Procter. I represent Yeda in this IPR
`matter.
` So a couple of things. I know you've
`been deposed in the past so I won't go through all
`the details about being deposed, but you submitted a
`lot of papers, they're very complicated, and I'll do
`my best to ask you questions that you'll understand
`if you'll agree to tell me when you don't understand
`my question. Is that fair?
` A Yes.
` Q The other thing is, in your declarations,
`there's talk about a three-times-a-week regimen and
`an alternate-day regimen. So today can we agree
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 8
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`9
`
`that when I say a three-times-a-week regimen or a
`three-times-weekly regimen, you'll understand that
`to mean a regimen where it's just three times a
`week?
` A Yes.
` Q And when I say alternate day or every
`other day, you'll understand that to mean a regimen
`where on one week you would give three
`administrations and on the next week you would give
`four.
` Is that fair?
` A Yes.
` (Exhibit 1, Exhibit 2, and Exhibit 3 were
`marked for identification and attached to the
`deposition transcript.)
`BY MR. JAMES:
` Q Maybe I'll just start off by marking your
`declarations that you submitted. We've marked as
`Peroutka 1 the declaration in the '250 IPR; Peroutka
`2, the declaration in the '413 IPR; and Peroutka 3,
`the declaration in the '302 IPR.
` A Thank you.
` Q And today I'm going to focus on the '250
`IPR, but if there's any time that you feel like you
`need to refer to any of the other papers, feel free
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 9
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`10
`
`to do so.
` A Thank you.
` Q Dr. Peroutka, I understand that you
`graduated with an M.D. degree from Johns Hopkins in
`1979?
` A Yes.
` Q And you got a Ph.D. from the same
`institution in 1980?
` A Yes.
` Q What was your thesis topic?
` A Multiple serotonin receptors.
` Q What is serotonin?
` A Serotonin is a neurotransmitter that is in
`the brain but also in the rest of the body. It acts
`as a neurotransmitter.
` Q And you studied serotonin receptors where,
`in the brain, the vagal nerve, or where?
` A Predominantly in the brain.
` Q Does serotonin or serotonin receptors,
`does that have any relationship to multiple
`sclerosis?
` MR. ANSTAETT: Objection, form.
` Q To the best of your knowledge.
` A To the best of my knowledge, no.
` Q After you graduated with your M.D. from
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 10
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`11
`
`Johns Hopkins and your Ph.D. in 1980, you did an
`internship at Stanford University, correct?
` A Correct.
` Q How long was that?
` A One year.
` Q After you finished your internship, then
`you did a fellowship back at Johns Hopkins; is that
`correct?
` A Residency and fellowship.
` Q Okay. And when did you finish that?
` A 1984.
` Q What did you do after that?
` A I became a faculty member at Stanford
`University in the departments of neurology and
`pharmacology.
` Q And what were your duties in the Stanford
`department of neurology?
` A The three main duties were to be a
`clinical neurologist and either -- and weekly see
`patients in the clinic and then multiple times a
`year for a month stretch be the attending physician
`in the neurology service in the hospital. Second
`was to teach the medical students, and the residents
`and the third was to run a laboratory.
` Q And your Ph.D. was a pharmacology Ph.D.,
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 11
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`12
`
`correct?
` A Technically, pharmacology and experimental
`therapeutics.
` Q But at Stanford you were working in the
`department of neurology.
` A I had a joint appointment also in
`pharmacology. I taught some pharmacology courses.
` Q What percentage of your time did you spend
`seeing patients during that time at Stanford?
` A Approximately a third.
` Q What percentage of that one third of your
`time did you see multiple sclerosis patients?
` A I would have to check and see the
`incidence of MS, whatever it is, but without going
`back and getting specifics, I would say in the 10 to
`20 percent range. It's a reasonably common
`disorder.
` Q Now, during that same period of time, you
`also worked at the VA, correct?
` A Correct, as part of it.
` Q Were the patients that you saw at the VA,
`were they predominantly men or women?
` A Men.
` Q Amongst those men, how many people had
`multiple sclerosis, roughly?
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 12
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`13
`
` A I honestly can't estimate at the VA
`system, in the VA system, how many showed up in
`clinic. Can you clarify specifically?
` Q The people that you were treating during
`your time treating patients at the VA, how many of
`those patients, roughly, would you say had MS?
` MR. ANSTAETT: Objection to form.
` A I honestly can't go back and estimate the
`exact number. I can give an estimate, a very rough
`estimate. It's about 10 percent.
` Q And is that roughly how the percentage --
`I'll strike that.
` In 1990, you went to work for
`Genentech, correct?
` A Correct.
` Q And in 1990, did you cease the practice of
`medicine?
` A I kept my license, I maintain my
`continuing medical education, my CME credit. So I
`still have an active license in the State of
`California.
` Q You have an active license today?
` A Correct.
` Q When was the last time you treated
`patients?
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 13
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`14
`
` A Treated patients for money, for
`compensation, was in 1990.
` Q 1990.
` What's the distinction between
`treating them for money and not treating them for
`money?
` A I occasionally get asked to do consults on
`patients, colleagues, friends, family members,
`individuals that want consulting services.
` Q But you last practiced medicine on a
`full-time basis in 1990.
` A Correct.
` Q And in 1990, what treatments were
`available for multiple sclerosis?
` A Not too many. Basically, we would use
`steroids acutely when there were exacerbations, and
`some people tried more immunosuppressive agents,
`but -- for the severe cases. I did see a number of
`severe cases. Some, vividly, I can still remember
`the name of the person, what he looked like, and how
`severely ill he was at the very end stage of MS.
` Q So steroids and immunosuppressants; is
`that correct?
` A Were the only available agents at that
`time.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 14
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`15
`
` Q There were no disease-modifying agents
`available at that time, correct?
` A Not on the market. I was aware of
`Dr. Bornstein and his work, but they were not -- it
`was a compassionate IND, perhaps, but they were not
`usually available.
` Q Have you ever treated a patient with
`glatiramer acetate?
` A No.
` Q You understand that glatiramer acetate is
`sometimes referred to as copolymer-1?
` A Yes.
` Q So if I use those terms today, you'll
`understand them to be interchangeable, at least for
`our purposes today?
` A I would prefer glatiramer acetate because
`that's how I refer to it.
` Q I understand, but, for example,
`Dr. Bornstein doesn't refer to the drug he was using
`as glatiramer acetate.
` A Correct.
` Q Since 1990, you've been employed in the
`pharmaceutical industry and as a consultant,
`correct?
` A Correct.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 15
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`16
`
` Q And you recently changed jobs, correct?
` A Correct.
` Q What's your new position?
` A I'm consulting at present.
` Q What's the name of the company that you
`work for?
` A I --
` Q Oh, you're just working -- okay.
` A I'm an independent consultant.
` Q I saw a reference on the Internet to
`Alkahest. What's that?
` A That was a company I was helping with for
`a few months to start up.
` Q That was this summer?
` A Yes.
` Q Now, over the course of your career as a
`consultant and working in the pharmaceutical
`industry, have you worked on projects having to do
`with MS?
` A Yes.
` Q What were those?
` A I was employed 2008 to 2011 at a company
`called PRA, the letters P-R-A, at the time
`International. They've since changed their name PRA
`Health Sciences. I was the vice president of
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 16
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`17
`
`neurosciences in what was called the therapeutic
`expertise group.
` So PRA at that point in time was the
`leading MS research organization at the CRO level.
`So what I mean by that is, at the time there were
`roughly -- I'm estimating again, but I think it's
`close -- 25,000 subjects around the world being
`studied for multiple sclerosis.
` Multiple sclerosis in 2008 was the
`most active area of clinical neuroscience research.
`There were many drugs being studied, the pipeline of
`pharmaceutical agents was very full, and PRA at the
`time did roughly one third of the global work. We
`had a preferred partner, who was a major company in
`the field of multiple sclerosis.
` So we would go -- over my three years
`there, I think, in the range of 30 different
`proposals for multiple sclerosis came in. It was my
`job to, number one, review the proposals to assess
`various aspects of the proposals. The entry
`criteria, the clinical end points for MS, the
`expected enrollment rates, where were the best
`places to go in terms of investigator sites. I
`would help and write for the companies, for the
`clients.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 17
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`18
` Secondly, I had to teach the internal
`people, who were not already up to speed on MS, what
`the current issues were in terms of various factors
`in the field, for example, placebos in MS, by that
`point in time, were becoming, in a sense,
`controversial. The Germans started and then the
`Europeans agreed that around that point in time it
`was becoming unethical, in many people's opinion, to
`treat an MS patient with a placebo because of the
`fact that there were so many agents available that
`were therapeutically beneficial, and it wasn't
`ethical to allow someone to be two years without
`treatment for the sake of a placebo study.
` Q So, during your time at PRA, you studied
`up on MS to educate your colleagues, right?
` MR. ANSTAETT: Object to form.
` Q Is that correct?
` A In part.
` Q In part.
` And you -- well, let's look at
`paragraph 6 of your declaration, if we could.
` MR. ANSTAETT: Bill, you're referring to
` Exhibit 1 here?
` MR. JAMES: I am, yes.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 18
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`19
`
`BY MR. JAMES:
` Q You have that, Doctor?
` A Yes.
` Q And in the middle of that paragraph, you
`say -- well, this is -- let me back up. This is a
`paragraph in which you talk about your work at PRA
`International, right?
` A Yes.
` Q And in the middle of that paragraph, you
`say you were "responsible for providing therapeutic
`expert advice on the design and development of human
`clinical trials for numerous neuropharmacological
`therapies," sorry, "neuropharmacological treatment
`therapies, including over 30 clinical trials for
`multiple sclerosis."
` Do you see that?
` A Yes.
` Q Now, a moment ago you referred to 30
`proposals.
` A Right.
` Q Do you recall that?
` Is that different than 30 clinical
`trials?
` A No. The proposals were for PRA to perform
`the work on the trials.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 19
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`20
`
` Q Where did that number 30 come from?
` A Reviewing my own records of just what I
`saw back in those days.
` Q So you have records from PRA from that
`time period?
` A General records.
` Q How many of those clinical trials that you
`consulted on related to glatiramer acetate?
` A I don't recall, and it's also
`confidential. I'm not really at liberty to
`disclose.
` Q Did any of them relate to glatiramer
`acetate?
` A To answer your question, which I would be
`happy to do if the confidentiality agreement that I
`have with PRA would allow it, and I'm not sure of
`that fact.
` Q I'm not asking you about details. I'm not
`asking you about who sponsored the clinical trial.
`I'm just asking you whether, sitting here today, you
`recall whether any of the clinical trials related to
`glatiramer acetate.
` A You are asking me to disclose the client.
` Q No, I'm not.
` MR. ANSTAETT: Wait a second, why don't
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 20
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`21
`
` we -- maybe we can take a break to just get
` Dr. Peroutka comfortable with what he can
` disclose.
` MR. JAMES: Why don't we do that during
` the next break, our first break, he can talk to
` you about that. I'll move on for now.
` MR. ANSTAETT: Okay.
` MR. JAMES: We'll just come back to that
` to see whether or not you can just tell me, yes
` or no, some of them related to glatiramer
` acetate.
`BY MR. JAMES:
` Q So other than your work at PRA, did you do
`any other work on multiple sclerosis between 1990
`and beginning work on this case?
` A Just keeping up with continuing medical
`education and the literature, reading the journal,
`routinely keeping up to speed with the new drug
`approvals, just general education.
` Q So you were aware when Copaxone was
`approved initially?
` A Yes.
` Q Do you remember what year that was?
` A I believe 1996.
` Q That's correct. And -- let me strike
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 21
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`22
`
`that.
` Do you consider yourself an expert in
`the mechanism of action of glatiramer acetate?
` MR. ANSTAETT: Objection, relevance.
` A I consider myself a person of ordinary
`skill in the art in terms of glatiramer acetate
`mechanisms.
` Q Do you consider yourself an expert in the
`mechanism of action of glatiramer acetate?
` MR. ANSTAETT: Objection, relevance, form.
` A Can you define "expert" for me, please.
` Q Just do you consider yourself to have
`expertise in your field. Would you hold yourself
`out to your colleagues as an expert in the mechanism
`of glatiramer acetate?
` MR. ANSTAETT: Objection, relevance.
` A I would consider myself of average
`expertise for a neurologist.
` Q Have you ever given a presentation on the
`mechanism of action of glatiramer acetate?
` A No.
` Q Now, you've been admitted as an expert in
`district court litigations in the past, correct?
` A Correct.
` Q What were the -- what was the subject
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 22
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`23
`
`matter of those litigations?
` A Pharmaceutical patents.
` Q Do you recall what the drugs were?
` A One was ondansetron, a 5-HT3 antagonist,
`Glaxo product.
` Q The other?
` A Frovatriptan, a migraine product.
`F-R-O-V-A-T-R-I-P-T-A-N.
` Q So you've never been submitted in a
`district court litigation as an expert in glatiramer
`acetate, correct?
` MR. ANSTAETT: Objection. Objection,
` relevance.
` A Can you clarify when you mean submitted,
`appeared in court, is that what you're --
` Q Yes.
` A No, I have not appeared in court.
` Q In those district court litigations, you
`held yourself out as an expert in 5-HT matters,
`correct?
` MR. ANSTAETT: Objection, form, relevance.
` A One was 5-HT3, which is actually a GI
`nausea drug, and the second was a migraine --
`migraine therapeutic.
` Q Which also has to do with serotonin,
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 23
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`24
`
`correct?
` MR. ANSTAETT: Objection, form.
` A Yes.
` Q In both cases you were submitted --
` MR. ANSTAETT: Bill, you have to give me a
` chance to get my objections on the record.
` Objection to form, and relevance.
` Q In both cases you were submitted, I'm
`sorry, strike that.
` In both cases you held yourself out
`to the district court as an expert in
`serotonin-receptor-related issues, correct?
` MR. ANSTAETT: Objection to form,
` relevance.
` A In those two instances, yes.
` Q Would you hold yourself out as an expert
`in the mechanism of action in glatiramer acetate in
`the same way?
` MR. ANSTAETT: Objection, form, relevance.
` A In terms of mechanism of action, which in
`my opinion has not been fully elucidated, I would
`consider myself as knowledgeable as a person of
`ordinary skill of the art.
` Q And your expertise arises from your study
`of the literature, keeping up with the literature
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 24
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`25
`
`over the last 25 years, correct?
` MR. ANSTAETT: Objection to form,
` relevance.
` A No, I would disagree, and I would say my
`expertise is also as a pharmacologist in
`understanding various aspects of drug development,
`how drugs are given to patients, assessing efficacy,
`safety, and tolerability.
` Q Have you ever performed a clinical trial
`studying glatiramer acetate?
` A It depends on the definition of "have I
`performed." I have been involved at PRA with
`performing trials where we looked at the trial. We
`recruited the investigators. I was helping in part
`of that. I helped with endpoint selection. So in
`that sense, as many investigators in the field, I
`was actively involved in studies of multiple
`sclerosis.
` Q My question was directed to glatiramer
`acetate specifically.
` A No.
` Q Have you ever designed a dosing regimen
`for a multiple sclerosis drug?
` A I would have to go back and review my --
`what I have available, which is actually very
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 25
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`26
`
`limited now; but I believe I provided consultative
`services as part of my job at PRA to certain
`companies on possible dosing regimens, but I cannot
`specifically cite at this point because I no longer
`have the information available; but I do recall a
`couple of small companies with MS drugs that we did
`discuss that issue.
` Q Have you ever designed a dosing regimen
`for a drug that exerts its effect without passing
`through the systemic circulation?
` MR. ANSTAETT: Objection to form.
` A I would have to give that some thought
`before answering.
` Q Sitting here right now, you can't think of
`one, correct? I'm not saying you can't go think of
`one later, but right now you can't think of one.
` A Well, give me a few minutes, let me just
`think.
` Q Well, why don't you think about it and
`we'll come back to it.
` MR. ANSTAETT: Wait. You can't -- you
` can't just ask him a question and then --
` MR. JAMES: I'll strike the question.
` A The answer is yes.
` Q Yes, okay, what drug was that?
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 26
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`27
` A Capsaicin, in my job at NeurogesX. It's a
`topically applied drug that acts by destroying the
`tips of the pain fibers in your skin. My job there,
`part of my job was -- we have a marketed product
`called Qutenza, Q-U-E-T-E-N-Z-A [sic]. It was a
`patch or is a patch. And we were designing a second
`generation lipid formulation. We had to determine
`at a local level how much of the liquid we could use
`compared to what was in the patch.
` Q Capsaicin, that's like a derivative of
`chili pepper, something like --
` A Yes, it's the active hot sauce component.
` Q That causes some inflammatory sort of
`reaction on the skin; is that right?
` A It can, yes.
` Q Does it cause the body to create
`antibodies to the capsaicin?
` A Not that I'm aware of.
` Q Are you aware of any topical inflammatory
`agents that will raise systemic antibodies?
` MR. ANSTAETT: Objection, relevance.
` A Topical inflammatory agents.
` Q Correct. Something that causes
`inflammation on the skin that raises systemic
`antibodies.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 27
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`28
`
` MR. ANSTAETT: Objection, relevance.
` A This isn't part of my report, and I would
`have to do more due diligence. I can think of at
`least one but --
` Q What's that?
` A Poison oak.
` Q Poison ivy has an agent in it that will --
` A I believe you create antibodies because
`then you react more, but I would have to
`double-check.
` Q So it's not necessary for a component or a
`composition or a drug to reach the systemic
`circulation in order for the body to form
`circulating antibodies, correct?
` MR. ANSTAETT: Objection, form, relevance.
` A Could you repeat the question, please.
` Q It's not necessary for an agent to reach
`the systemic circulation in order for the body to
`create circulating systemic antibodies, correct?
` MR. ANSTAETT: Same objections.
` A I'm not sure that that's correct.
` Q Well, with respect to poison ivy, it
`raises IgE antibodies throughout the body, correct?
` MR. ANSTAETT: Objection to form,
` foundation, relevance.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 28
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`29
` A You're outside the scope of my report, and
`you're asking me questions that are answerable with
`some due diligence of looking into the database,
`but --
` Q In your report, you said that the presence
`of circulating antibodies reflects that the drug is
`in the systemic circulation, correct?
` A Could you point that out specifically?
` Q We'll come back to that. So you don't
`recall saying that?
` MR. ANSTAETT: Objection to form.
` Doctor, you've got to pause after
` Mr. James asks his question so I can insert my
` objections, and you also have to let Mr. James
` finish his questions before you start your
` answer.
` Objection to form.
` Q Would you like to have the question read
`back?
` A Yes, please.
` (Record read.)
` A I do recall that statement, but I would
`like to see it in context so I could interpret it
`properly.
` Q We'll come back to that.
`
`The Little Reporting Company
` (646) 650-5055 | www.littlereporting.com
`
`IPR2015-00644
`
`EXHIBIT NO. 1066 PAGE 29
`
`

`
`1
`2
`3
`4
`5
`6
`7
`8
`9
`10
`11
`12
`13
`14
`15
`16
`17
`18
`19
`20
`21
`22
`23
`24
`25
`
`30
`
` So since 1990, Doctor, how many MS
`patients have you treated?
` A None, as a physician, practicing
`physician, but in terms of clinical trials, I was
`the therapeutic expert on multiple MS trials.
` Q Are you an immunologist?
` A No.
` Q If you could look at paragraph 1 of your
`report. The second sentence of that paragraph says
`"Throughout my career, I have practiced as a
`clinician in the field of neurology, conducted
`research in multiple neurological disorders
`including multiple sclerosis, and held a number of
`relevant positions in the biotechnology and
`pharmaceutical industry."
` Do you see that?
` A Yes.
` Q So it's not true that you've been
`practicing as a clinician in the field of neurology
`throughout your career, is it?

This document is available on Docket Alarm but you must sign up to view it.


Or .

Accessing this document will incur an additional charge of $.

After purchase, you can access this document again without charge.

Accept $ Charge
throbber

Still Working On It

This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.

Give it another minute or two to complete, and then try the refresh button.

throbber

A few More Minutes ... Still Working

It can take up to 5 minutes for us to download a document if the court servers are running slowly.

Thank you for your continued patience.

This document could not be displayed.

We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.

Your account does not support viewing this document.

You need a Paid Account to view this document. Click here to change your account type.

Your account does not support viewing this document.

Set your membership status to view this document.

With a Docket Alarm membership, you'll get a whole lot more, including:

  • Up-to-date information for this case.
  • Email alerts whenever there is an update.
  • Full text search for other cases.
  • Get email alerts whenever a new case matches your search.

Become a Member

One Moment Please

The filing “” is large (MB) and is being downloaded.

Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.

Your document is on its way!

If you do not receive the document in five minutes, contact support at support@docketalarm.com.

Sealed Document

We are unable to display this document, it may be under a court ordered seal.

If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.


Access Government Site

We are redirecting you
to a mobile optimized page.





Document Unreadable or Corrupt

Refresh this Document
Go to the Docket

We are unable to display this document.

Refresh this Document
Go to the Docket